Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
South San Francisco, CA, February 25, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the closing of its previously announced underwritten public offering of 4,375,000 shares of its common stock, as well as 656,250 additional shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional shares. The public offering price was $8.00 per share and total net proceeds to Cytokinetics from the public offering are expected to be approximately $37.4 million, after deducting the underwriting discount and estimated offering expenses payable by Cytokinetics.
Cytokinetics intends to use the net proceeds from this public offering for research and development and other general corporate purposes, including working capital.
Cowen and Company, LLC acted as the sole book-running manager. JMP Securities LLC acted as lead manager and Canaccord Genuity Inc. as a co-manager of the offering.
This offering was made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (the "SEC"). A preliminary and final prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from Cowen and Company, LLC c/o Broadridge Financial Services., 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
This press release contains forward-looking statements, including statements relating to Cytokinetics' expectations regarding the use of proceeds of the offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and Cytokinetics cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to the estimated proceeds from the offering and use of such proceeds. Risks and uncertainties relating to Cytokinetics and this offering can be found in the "Risk Factors" section of the final prospectus supplement related to such offering filed with the SEC. Cytokinetics undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Cytokinetics' expectations.
Joanna L. Goldstein (Manager, Investor Relations & Corporate Communications)